VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy

JAMA Ophthalmology

Volumn 132, Issue 5, 2014, Pages 521-527

  Hagstrom, Stephanie A ^a,b   Ying, Gui Shuang ^c   Pauer, Gayle J T ^a   Sturgill Short, Gwen M ^a   Huang, Jiayan ^c   Maguire, Maureen G ^c   Martin, Daniel F ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ALLELE; ARTICLE; CLINICAL TRIAL; DNA POLYMORPHISM; FLUORESCENCE ANGIOGRAPHY; GENE FREQUENCY; GENOTYPE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; PHARMACOGENETICS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

AGED; ALLELES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GENE FREQUENCY; GENOTYPE; HUMANS; MACULAR DEGENERATION; MALE; POLYMORPHISM, GENETIC; RETINA; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84900410891     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.109     Document Type: Article

References (41)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
2. Augustin AJ, Offermann I. Emerging drugs for age-related macular degeneration. Expert Opin Emerg Drugs. 2006;11(4):725-740.
3. Martin DF,Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
4. Martin DF,Maguire MG, Fine SL, et al; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
5. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial [published corrections appear in Ophthalmology. 2012;119(8):1508 and 2013;120(9):1719] Ophthalmology. 2012;119(7):1399-1411.
6. Krebs I, Schmetterer L, Boltz A, et al; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266-271.
7. Priya RR, Chew EY, SwaroopA. Genetic studies of age- relatedmaculardegeneration: lessons, challenges, and opportunities for disease management. Ophthalmology. 2012;119(12):2526-2536.
8. Agosta E, Lazzeri S, Orlandi P, et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics. 2012;13(9):1037-1053.
9. Hagstrom SA, Ying GS, Pauer GJ, et al; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013;120(3):593-599.
10. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 2006;47(1):329-335.
11. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet. 2006;15(19):2955-2961.
12. Janik-Papis K, Zaras M, Krzyzanowska A, et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol. 2009;87(3):234-238.
13. Almeida LN, Melilo-Carolino R, Veloso CE, et al. Homozygosity for the +674CT polymorphism on VEGF gene is associated with age-related macular degeneration in a Brazilian cohort. Graefes Arch Clin Exp Ophthalmol. 2012;250(2):185-189.
14. Galan A, Ferlin A, Caretti L, et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology. 2010;117(9):1769-1774.
15. Lazzeri S, Orlandi P, Figus M, et al. The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. ScientificWorld-Journal. 2012:420190. doi:10.1100/2012/420190.
16. Lin JM,Wan L, Tsai YY, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol. 2008;145(6):1045-1051.
17. Richardson AJ, Islam FM, Guymer RH, CainM, Baird PN. A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis. 2007;13:2148-2152.
18. Boekhoorn SS, Isaacs A, Uitterlinden AG, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology. 2008;115(11):1899-1903.
19. Fang AM, Lee AY, Kulkarni M, OsbornMP, BrantleyMA Jr. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol Vis. 2009;15:2710-2719.
20. Lu Y, Shi Y, Xue C, Yin J, Huang Z. Pooled-Analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration. Mol Biol Rep. 2012;39(6):6547-6553.
21. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-Angiogenic therapy. Pharmacogenomics. 2007;8(1):49-66.
22. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-Angiogenic therapeutics? Nat Rev Cancer. 2008;8(11):880-887.
23. McKibbinM, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol. 2012;96(2):208-212.
24. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci. 2011;52(7):4694-4702.
25. Nakata I, Yamashiro K, Nakanishi H, Tsujikawa A, Otani A, Yoshimura N. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol. 2011;55(5):435-443.
26. Abedi F, Wickremasinghe S, Richardson AJ, et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):115-121.
27. Lazzeri S, Figus M, Orlandi P, et al. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics. 2013;14(6):623-630.
28. Boltz A, Rui M, Jonas JB, et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology. 2012;119(8):1615-1620.
29. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
30. Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol. 2006;124(2):193-198.
31. Grunwald JE, Daniel E, Ying GS, et al; CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2012;119(8):1634-1641.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B. 1995;57(1): 289-300.
33. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
34. Brown DM, Kaiser PK, MichelsM, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
35. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
36. Imai D, Mori K, Horie-Inoue K, et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor. 2010;3(2):53-59.
37. Immonen I, Seitsonen S, Tommila P, et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology. 2010;117(1):103-108.
38. Vailati FB, Crispim D, Sortica DA, Souza BM, Brondani LA, Canani LH. The C allele of-634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue. Invest Ophthalmol Vis Sci. 2012;53(10):6411-6415.
39. Flicek P, Ahmed I, Amode MR, et al. Ensembl 2013. Nucleic Acids Res. 2013;41(database issue):D48-D55.
40. Yuan HY, Chiou JJ, Tseng WH, et al. FastSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34(web server issue):W635-W641.
41. Lotery AJ, Gibson J, Cree AJ, et al. Alternative Treatments to Inhibit VEGF in PatientsWith Age-Related Choroidal Neovascularisation (IVAN) Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-relatedmacular degeneration in the IVAN Study. Ophthalmology. 2013;120(12):2637-2643.